将激动剂逆转为抑制剂:mTOR降解剂的发展
Liquan Zhu1, Siyi Fu2, Longfei Ma2
1Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, 310014, PR China; General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, 310014, PR China.
研究人员使用激动剂开发了新的mTOR向PROTAC,证明了有效的蛋白质降解. 这一新战略扩大了针对蛋白质降解的治疗应用.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 通过化向化基体 (PROTACs) 向蛋白质降解是调节蛋白质功能的关键策略.
- 传统的PROTAC设计使用抑制剂作为弹头.
研究的目的:
- 开发使用激动剂作为弹头的新型mTOR准PROTAC.
- 评估这些PROTACs在降解mTOR和抑制细胞增殖方面的有效性.
主要方法:
- mTOR激动剂MHY-1485与Cereblon (CRBN) 连接物利多米德的结合.
- 系统选,以识别有力的PROTAC分子.
- 蛋白质组分析以确定下游目标和受PROTACs影响的途径.
主要成果:
- 鉴定PD-M6,一个强大的PROTAC降解mTOR (DC50 = 4.8微米).
- PD-M6逆转了激素作用,抑制了细胞增殖 (IC50 = 11.3微米),并诱导了自.
- 蛋白质组分析显示PD-M6降低了关键的mTOR通路蛋白质的调节,包括LAMTOR1,MAPKAP1和CASTOR1,具有特定的LAMTOR1降解.
结论:
- 激动剂可以有效地被用作针对蛋白质降解的弹头 PROTAC设计.
- PD-M6代表了一种具有治疗潜力的新型双功能分子.
- 这种方法扩大了PROTAC技术在药物发现方面的实用性.
更多相关视频
08:04Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
09:37A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Desensitization and Tachyphylaxis
Inhibition of Cdk Activity
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
